香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 Sirnaomics Ltd. Sirnaomics Ltd. 聖 諾 醫 藥 * （ 於開曼群島註冊成立之有限公司） （股份代號：2257） 自願性公告 董事增持本公司股份 本公告乃由Sirnaomics Ltd.（「本公司」，連同其附屬公司統稱「本集團」）自願 作出。 本公司董事會（「董事會」）獲本公司執行董事兼主席潘洪輝博士（「潘博士」） 告 知 ， 潘 博 士 已 於 2026 年 3 月 30 日 以 其 個 人 資 金 於 公 開 市 場 按 每 股 股 份 約 5.93 港 元 的 平 均 價 格 購 入 合 共 38,000 股 本 公 司 普 通 股（「 股 份 」）。 ...

RNAi Therapy Pipeline - Sirnaomics achieved significant progress in its RNAi therapy pipeline, particularly with STP705 for non-melanoma skin cancer and localized fat reduction, advancing to Phase III clinical trials[3] - The Phase I clinical trial for STP705 in localized fat reduction demonstrated excellent safety and efficacy, with minimal local skin reactions, and plans to progress to Phase II are underway[4] - The Phase I clinical study of STP707 for advanced solid tumors involved 50 patients and showed good safety and efficacy, especially in pancreatic cancer patients[4] - The complete Phase I clinical study report for STP707 has been submitted to the FDA, confirming stable disease activity, particularly in pancreatic cancer patients[4] - Sirnaomics aims to commercialize STP705 with a target for a New Drug Application (NDA) submission by 2027, depending on regulatory approval and funding conditions[10] - STP705's Phase II/III pivotal trial preparations have been completed, with positive safety data from 69 patients with invasive squamous cell carcinoma (isSCC) and 30 patients with basal cell carcinoma (BCC) reported[19] - The medical aesthetics product STP705FR achieved significant progress with excellent safety results in its Phase I trial, showing minimal local skin reactions and promising early efficacy signals[21] - STP122G has entered the final cohort of its Phase I clinical trial and received FDA approval for accelerated testing, aiming for a transition to Phase II[24] - The company plans to initiate Phase II clinical trials for STP705FR in Q1 2026, building on the promising results from its Phase I trial[21] - The ongoing development of STP355 and STP369 aligns with the company's strategy to prioritize key PNP assets for late-stage development[20] Intellectual Property and Patents - Sirnaomics has approximately 90 patents in its intellectual property portfolio, including 28 approved patents, covering PNP and GalAhead™ platforms[10] - The PNP delivery platform is one of the few clinically validated extrahepatic siRNA delivery systems globally, while the GalAhead™ platform is the only programmable RNAi platform undergoing global clinical development[14] - The PNP platform's patent coverage has expanded, with new applications covering STP705/707 clinical formulations and production process optimizations[31] - The GalAhead™ platform's patent foundation has been strengthened with a granted US patent, covering programmable pharmacokinetic designs and specific formulations[32] - The company has maintained IP protection for clinical candidates STP705 and STP122G/125G, ensuring the uniqueness of late-stage assets[34] - As of December 31, 2025, the company has over 110 patents and pending applications globally, an increase of more than 10 filings from 2024[35] Financial Performance - For the fiscal year ending December 31, 2025, the group reported no revenue, while for the fiscal year ending December 31, 2024, revenue was $1.8 million[12] - The net loss for the fiscal year ending December 31, 2025, was $14.6 million, a reduction from $50.2 million for the fiscal year ending December 31, 2024[13] - The group's administrative expenses decreased by 71% from $17.2 million for the fiscal year ending December 31, 2024, to $5.0 million for the fiscal year ending December 31, 2025[13] - Research and development expenses decreased by 50% from $20.8 million for the fiscal year ending December 31, 2024, to $10.3 million for the fiscal year ending December 31, 2025[13] - The fair value gain on financial liabilities decreased from $6.9 million for the fiscal year ending December 31, 2024, to $1.7 million for the fiscal year ending December 31, 2025[12] - The group recorded other gains and losses of $0.7 million for the fiscal year ending December 31, 2025, an increase of 3,595% from $20,000 for the fiscal year ending December 31, 2024[63] - The company reported total comprehensive expenses of $14,638,000 for the fiscal year 2025, compared to $50,647,000 in 2024, showing a decrease in overall losses[122] - Basic and diluted loss per share for the fiscal year 2025 was $(0.15), compared to $(0.66) in 2024, indicating an improvement in per-share performance[122] Cost Management and Restructuring - A comprehensive restructuring plan is being implemented to enhance operational efficiency and streamline the organizational structure[7] - The company is focusing on aggressive cost-cutting measures and reallocating resources to high-potential programs, prioritizing the development of STP705 and STP122G[7] - The company implemented a cost reduction plan, achieving over 70% reduction in non-essential operating expenses, exceeding 2024 budget targets[51] - Monthly cash burn decreased by approximately 60% compared to 2024 levels, ensuring sufficient cash runway for strategic initiatives in 2026 and 2027[52] - The company is implementing a restructuring plan aimed at improving operational efficiency and reducing cash outflows from operations[128] Clinical Development and Trials - The company is focused on advancing its RNAi therapeutic product line and aims to become a global leader in RNA-based therapies[11] - The company is conducting various phases of clinical trials, including I, II, and III phases, to evaluate drug safety, efficacy, and optimal dosing[176][177] - The III phase trials involve a larger patient population to statistically assess the product's efficacy and safety for regulatory approval[177] - The company is utilizing proprietary peptide-lipid nanoparticles (PLNP) for drug delivery in its clinical research[177] - Serious adverse events (SAE) are defined as any medical event in human drug trials that could lead to significant health risks or require hospitalization[178] Market and Competitive Landscape - The global RNAi therapy market is maturing, with trends indicating a shift towards extrahepatic delivery and programmable patient-centric dosing methods[45] - The market analysis indicates a growing demand for RNAi therapies in chronic cardiovascular and metabolic conditions, driven by payer preferences for long-acting, low-burden therapies[46] - Sirnaomics' PNP and GalAhead™ platforms create a unique competitive moat, with few industry peers possessing clinically validated extrahepatic delivery systems[47] - The medical aesthetics market shows high growth potential, with STP705's new mechanism of action and mild local skin reactions differentiating it from existing procedures[48] Governance and Compliance - The company has adopted and applied the corporate governance code as per the listing rules, ensuring compliance with all applicable provisions during the reporting period[99] - The company has re-complied with the listing rules after appointing new directors and committee members following the resignation of previous members[100] - The company has established its own code of conduct regarding securities trading, which meets or exceeds the standards set forth in the standard code[101] - The audit committee, consisting of three independent non-executive directors, reviewed the consolidated financial statements for the year ending December 31, 2025[103] - The independent auditor has issued a qualified opinion on the consolidated financial statements for the year ending December 31, 2025, highlighting significant uncertainties related to going concern[109] Investment and Financing - The company has made significant investments totaling $20 million in an independent investment portfolio, aimed at enhancing returns through idle cash and participating in various securities markets[82] - The company raised approximately $6.8 million from the subscription of 4,555,362 new shares after deducting all applicable costs and expenses[97] - The company issued 17,527,696 new shares at a subscription price of HKD 3.36 per share, raising approximately $7.5 million net after costs, intended for general working capital[94] - The company has established a new subsidiary, Zhongshan Sirnaomics, with a registered capital of RMB 6,000,000 as of August 6, 2025[153] Future Outlook - The company is focused on advancing its core products while managing cash flow and financial obligations effectively[128] - The group aims to continue advancing its innovative RNAi therapy pipeline and explore new therapeutic areas despite current economic challenges[57] - The company is actively exploring global and local partnership opportunities for its key products, aiming to accelerate the development of multiple clinical assets[56] - The financial strategy for 2026 includes strict cost control on non-core expenditures while seeking flexible investment opportunities in high-return projects[55]

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 Sirnaomics Ltd. 聖 諾 醫 藥 * （ 於開曼群島註冊成立之有限公司） （股份代號：2257） 建議終止2022年受限制股份單位計劃 及 建議採納2026年受限制股份單位計劃 董 事 會 欣 然 宣 佈 ， 於 2026 年 3 月 24 日（ 交 易 時 段 後 ）， 董 事 會 議 決 建 議 終 止 2022年 受 限 制 股 份 單 位 計 劃 及採 納 2026 年 受限 制 股 份 單 位 計 劃 ， 並 由 股 東 於本公司將召開的股東特別大會上批准。 建議終止2022年受限制股份單位計劃及建議採納2026年受限制股份單 位計劃 2022年受限制股份單位計劃乃由本公司於2022年4月22日採納，自採納日期 起 計有 效期 為 ...

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 Sirnaomics Ltd. 聖 諾 醫 藥 * （ 於開曼群島註冊成立之有限公司） （股份代號：2257） 董事會會議通告 Sirnaomics Ltd.（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於2026年 3 月 27 日（ 星 期 五 ）舉 行 董 事 會 會 議 ， 藉 以（ 其 中 包 括 ）考 慮 並 批 准 本 公 司 及 其附屬公司截至2025年12月31日止年度業績及其發佈。 承董事會命 Sirnaomics Ltd. 主席兼執行董事 潘洪輝 香港，2026年3月13日 於 本 公 告 日 期 ， 董 事 會 包 括 執 行 董 事 潘 洪 輝 博 士 、 非 執 行 董 事 歐 陽 雲 龍 先 生 及殷 惠 軍 博 士 ...

| 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) 02257 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | 於下列日期開始時的結存(註1) 2026年2月28日 | | 107,221,538 | | | 0 | | | 107,221,538 | | 1). 配售/認購 - 涉及新股 | | 2,500,000 | 2.33 % | | HKD | 12 | | | | 根據2025年9月7日之認購協議， ...

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 Sirnaomics Ltd. 聖 諾 醫 藥 * （ 於開曼群島註冊成立之有限公司） （股份代號：2257） 部分完成根據一般授權認購新股份及終止認購協議 茲提述Sirnaomics Ltd.（「本公司」）日期為2025年9月7日、2025年9月17日及 2025年12月7日有關認購事項之公告（「該等公告」）。除另有界定外，本公告 所用詞彙與該等公告所界定者具有相同涵義。 部分完成認購協議A 認購協議A於2026年3月7日部分完成，並以每股認購股份12.00港元向認購 人A發行2,500,000股新股份（「認購事項A部分完成」）。 – 1 – 對本公司股權架構的影響 經 友 好 誠 信 協 商 後 ， 本 公 司 與 認 購 人 A 一 致 同 意 於 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 聖諾醫藥 (*僅供識別) 呈交日期: 2026年3月4日 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 02257 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 107,221,538 0 107,221,538 增加 / 減少 (-) 0 0 本月底結存 107,221,538 0 107,221,538 足夠公眾持股量的確認(註4) I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02257 | 說明 | | | | | | | | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 致：香港交易及結算所有限公司 公司名稱: 聖諾醫藥 (*僅供識別) | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02257 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 230,000,000 | USD | | 0.001 | USD | | 230,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 230,000,000 | USD | | 0.001 | USD | | 230,000 | 本月底法定/註冊股本總額： USD 230,000 FF301 第 1 頁 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 聖諾醫藥 (*僅供識別) 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02257 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 230,000,000 | USD | | 0.001 USD | | 230,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 230,000,000 | USD | | 0.001 USD | | 230,000 | III.已發行股份及/或庫存股份變動詳情 本月底法定/註冊 ...

Core Viewpoint - The biopharmaceutical industry in China experienced a volatile year in 2025, with significant growth in the first half followed by a sharp decline in the latter half, indicating a restructuring of the underlying logic of the industry [1][2][28]. Group 1: Industry Performance - The innovative drug sector saw explosive growth in the first half of 2025, with the China Innovation Drug Index rising by 13.43% and the Hong Kong Innovation Drug Index increasing by 60% [1][27]. - By December 28, 2025, the Hong Kong Innovation Drug Index had dropped over 20% since September, with many unprofitable biotech companies experiencing declines of over 40% [1][27]. Group 2: Policy Support - In 2025, the policy environment for biopharmaceuticals in China evolved to integrate national and local support, creating a comprehensive system for innovative drug development [4][30]. - Key policy initiatives included the release of measures to support innovative drug development, focusing on research support, inclusion in insurance, and clinical application [4][30]. - The introduction of a 30-day expedited review process for innovative drug clinical trial applications was implemented to enhance efficiency [4][30]. Group 3: Technological Advancements - The integration of AI in drug development accelerated in 2025, with AI tools becoming standard in pharmaceutical research and development [14][39]. - AI-driven companies like Insilico Medicine achieved significant milestones, including the rapid progression of drug candidates through clinical trials [14][40]. Group 4: Payment System Changes - The payment landscape for innovative drugs shifted from a focus on the lowest price to a more balanced approach that considers quality and reasonable pricing [16][42]. - The introduction of a commercial health insurance directory for innovative drugs marked a significant development, allowing for better access and affordability for patients [19][45]. Group 5: Business Development Transactions - The business development (BD) landscape in the innovative drug sector transitioned from a phase of enthusiasm to a more rational evaluation of value [22][48]. - By the end of 2025, the total amount of overseas licensing agreements in China's innovative drug sector exceeded $130 billion, setting a historical record [50]. - However, market reactions to BD announcements became more subdued, with significant stock price declines following major deals, indicating a reassessment of the quality and sustainability of such transactions [50][51].